阅读说明：本技术 基于clec9a的嵌合蛋白复合物 (CLEC 9A-based chimeric protein complex ) 是由 N·克雷 E·德普拉 L·扎比奥 J·塔威尼尔 于 2020-03-27 设计创作，主要内容包括：本发明部分地涉及嵌合蛋白复合物及其作为治疗剂的用途,所述嵌合蛋白复合物包括抗Clec9A靶向部分、经修饰的Fc结构域和经修饰的人IFNa。本发明还涉及包含所述嵌合蛋白复合物的药物组合物以及所述药物组合物在治疗各种疾病中的用途。(The present invention relates, in part, to chimeric protein complexes comprising an anti-Clec 9A targeting moiety, a modified Fc domain, and a modified human IFNa, and their use as therapeutics. The invention also relates to pharmaceutical compositions comprising said chimeric protein complexes and to the use of said pharmaceutical compositions in the treatment of various diseases.)

1. A chimeric protein complex, comprising:

(i) a targeting moiety that specifically binds to C-type lectin domain family 9 member A (Clec9A),

(ii) modified human IFN alpha 2, and

(iii) a modified Fc domain.

2. The chimeric protein complex of claim 1, wherein the chimeric protein complex is a heterodimer.

3. The chimeric protein complex of claim 2, wherein the chimeric protein complex comprises a polypeptide having an amino acid sequence at least 95%, or at least 98%, or at least 99% identical to any one of SEQ ID NOs 1-4 and 43.

4. The chimeric protein complex of claim 1, wherein the chimeric protein complex comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs 1-4 and 43 and having fewer than 10 mutations relative to the amino acid sequence.

5. The chimeric protein complex of claim 4, wherein the chimeric protein complex comprises a polypeptide having an amino acid sequence selected from SEQ ID NOs 1-4 and 43 and having fewer than 5 mutations relative to the amino acid sequence.

6. The chimeric protein complex of claim 1, wherein the chimeric protein complex comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs 1-4 and 43.

7. The chimeric protein complex of any one of claims 1 to 6, wherein the chimeric protein complex further comprises a polypeptide having an amino acid sequence at least 95% identical to any one of SEQ ID NOs 5-8, 29-36, or 41-42.

8. The chimeric protein complex of claim 7, wherein the chimeric protein complex further comprises a polypeptide having an amino acid sequence with at least 98% identity to any one of SEQ ID NOs 5-8, 29-36, or 41-42.

9. The chimeric protein complex of claim 8, wherein the chimeric protein complex further comprises a polypeptide having an amino acid sequence with at least 99% identity to any one of SEQ ID NOs 5-8, 29-36, or 41-42.

10. The chimeric protein complex of any one of claims 7 to 9, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NO 1 or 3, and

(ii) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NO 5 or 6.

11. The chimeric protein complex of claim 10, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NO 1 or 3, and

(ii) a polypeptide having an amino acid sequence with at least 98% identity to any one of SEQ ID NO 5 or 6.

12. The chimeric protein complex of claim 11, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NO 1 or 3, and

(ii) a polypeptide having an amino acid sequence with at least 99% identity to any one of SEQ ID NO 5 or 6.

13. The chimeric protein complex of any one of claims 7 to 9, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NO 2 or 4, and

(ii) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NO 7 or 8.

14. The chimeric protein complex of claim 13, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NO 2 or 4, and

(ii) a polypeptide having an amino acid sequence with at least 98% identity to any one of SEQ ID NO 7 or 8.

15. The chimeric protein complex of claim 14, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NO 2 or 4, and

(ii) a polypeptide having an amino acid sequence with at least 99% identity to any one of SEQ ID NO 7 or 8.

16. The chimeric protein complex of any one of claims 7 to 9, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 95% identity to SEQ ID NO 2, and

(ii) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NO 31 or 32.

17. The chimeric protein complex of claim 16, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID NO 2, and

(ii) a polypeptide having an amino acid sequence with at least 98% identity to any one of SEQ ID NO 31 or 32.

18. The chimeric protein complex of claim 17, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID NO 2, and

(ii) a polypeptide having an amino acid sequence with at least 99% identity to any one of SEQ ID NO 31 or 32.

19. The chimeric protein complex of any one of claims 7 to 9, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO 43, and

(ii) a polypeptide having an amino acid sequence with at least 95% identity to any of SEQ ID NO 41 or 42.

20. The chimeric protein complex of claim 16, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID NO 43, and

(ii) a polypeptide having an amino acid sequence with at least 98% identity to any one of SEQ ID NO 41 or 42.

21. The chimeric protein complex of claim 17, wherein the chimeric protein complex comprises:

(i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID NO 43, and

(ii) a polypeptide having an amino acid sequence with at least 99% identity to any one of SEQ ID NO 41 or 42.

22. The chimeric protein complex of any one of claims 1 to 21, wherein the modified human IFN α 2 has an amino acid sequence with at least 95% identity to SEQ ID No. 9 or 10.

23. The chimeric protein complex of claim 22, wherein the modified human IFN α 2 has an amino acid sequence with at least 98% identity to SEQ ID No. 9 or 10.

24. The chimeric protein complex of claim 23, wherein the modified human IFN α 2 has an amino acid sequence with at least 99% identity to SEQ ID No. 9 or 10.

25. The chimeric protein complex of any one of claims 1 to 24, wherein the modified human IFN α 2 has 1-3 mutations relative to amino acid sequence SEQ ID No. 9 or 10.

26. The chimeric protein complex of claim 25, wherein the modified human IFN α 2 comprises a R149A mutation relative to SEQ ID No. 9 or 10, or one of R33A, R144A, R144I, R144L, R144S, R144T, R144Y, a145D, a145G, a145H, a145K, a145Y, M148A, and L153A mutations relative to SEQ ID No. 9 or 10, optionally a 145G.

27. The chimeric protein complex of any one of claims 1 to 26, wherein the chimeric protein complex comprises a recombinant heavy chain-only antibody (VHH).

28. The chimeric protein complex of claim 27, wherein VHH has an amino acid sequence with at least 95% identity to one of SEQ ID NOs 11 or 12.

29. The chimeric protein complex of claim 28, wherein VHH has an amino acid sequence with at least 98% identity to one of SEQ ID NOs 11 or 12.

30. The chimeric protein complex of claim 29, wherein VHH has an amino acid sequence with at least 99% identity to one of SEQ ID NOs 11 or 12.

31. The chimeric protein of claim 30, wherein the VHH has the amino acid sequence of any one of SEQ ID NOs 11 and 12.

32. The chimeric protein complex of any one of claims 1 to 31, wherein the modified Fc domain comprises one or more of the following mutations relative to any one of SEQ ID NOs 13-16: P329G, K322Q, K322A or P331S.

33. The chimeric protein complex of claim 32, wherein the modified Fc domain comprises one or more of the following mutations relative to human IgG1 Fc: P329G, K322Q, K322A or P331S.

34. The chimeric protein complex of claim 32 or 33, wherein the modified Fc domain has an amino acid sequence with at least 90% identity to SEQ ID NOs 13-16.

35. The chimeric protein complex of claim 32 or 33, wherein the modified Fc domain has an amino acid sequence with at least 93% identity to SEQ ID NOs 13-16.

36. The chimeric protein complex of claim 32 or 33, wherein the modified Fc domain has an amino acid sequence with at least 95% identity to SEQ ID NOs 13-16.

37. A method for treating or preventing cancer, the method comprising administering to a patient in need thereof an effective amount of the chimeric protein complex of any of the above claims.

38. The method of claim 37, wherein the cancer is selected from one or more of: basal cell carcinoma; biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancers; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancers of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); a glioblastoma; liver cancer; hepatoma; an intraepithelial neoplasm; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); melanoma; a myeloma cell; neuroblastoma; oral cancer (lip, tongue, mouth and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland cancer; sarcomas (e.g., kaposi's sarcoma); skin cancer; squamous cell carcinoma; gastric cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas, including hodgkin's and non-hodgkin's lymphomas, and B-cell lymphomas (including low grade/follicular non-hodgkin's lymphomas (NHLs); small Lymphocytic (SL) NHL; intermediate/follicular NHL; intermediate diffuse NHL; higher-grade immunocytogenic NHL; higher lymphoblastic NHL; high-grade small non-nucleated cell NHL; giant-mass NHL; mantle cell lymphoma; AIDS-related lymphomas; and waldenstrom's macroglobulinemia; chronic Lymphocytic Leukemia (CLL); acute Lymphoblastic Leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), and abnormal vascular proliferation associated with nevus maculatus hamartoma; edema (e.g., edema associated with brain tumors); and megs syndrome.

39. A pharmaceutical composition comprising the chimeric protein complex of any one of claims 1-36 and a pharmaceutically acceptable carrier.

40. A method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of claim 39.

41. The method of claim 40, wherein the cancer is selected from one or more of: basal cell carcinoma; biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancers; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancers of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); a glioblastoma; liver cancer; hepatoma; an intraepithelial neoplasm; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); melanoma; a myeloma cell; neuroblastoma; oral cancer (lip, tongue, mouth and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland cancer; sarcomas (e.g., kaposi's sarcoma); skin cancer; squamous cell carcinoma; gastric cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas, including hodgkin's and non-hodgkin's lymphomas, and B-cell lymphomas (including low grade/follicular non-hodgkin's lymphomas (NHLs); small Lymphocytic (SL) NHL; intermediate/follicular NHL; intermediate diffuse NHL; higher-grade immunocytogenic NHL; higher lymphoblastic NHL; high-grade small non-nucleated cell NHL; giant-mass NHL; mantle cell lymphoma; AIDS-related lymphomas; and waldenstrom's macroglobulinemia; chronic Lymphocytic Leukemia (CLL); acute Lymphoblastic Leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), and abnormal vascular proliferation associated with nevus maculatus hamartoma; edema (e.g., edema associated with brain tumors); and megs syndrome.

42. A recombinant nucleic acid composition encoding one or more chimeric protein complexes or components thereof of any one of claims 1-36.

43. A host cell comprising the nucleic acid of claim 42.

44. The chimeric protein complex of any one of claims 1-36, wherein the chimeric protein complex has an orientation and/or configuration as shown in figure 1 or figure 7.

45. A multivalent or bivalent chimeric protein complex, comprising:

a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 17 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 7;

a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 2 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 19;

a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 18 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 7;

a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 20 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 7;

polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 2 and polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 22; or

Polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 21 and polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 7.

46. A method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a multivalent or bivalent chimeric protein complex of claim 45.

47. A chimeric protein complex comprising at least two polypeptides having a sequence at least 95%, or 97%, or 98%, or 99%, or 100% identical to the amino acid sequence of any one of SEQ ID nos 1-43.

48. A method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of the chimeric protein complex of claim 47.

Technical Field

The present invention relates in part to a chimeric protein complex comprising a fragment crystallizable domain (Fc), Clec9A VHH as a targeting moiety, and modified interferon alpha 2(IFN alpha 2) as a signaling agent. The use of these chimeric protein complexes as therapeutic agents is also disclosed.

Sequence listing

This application contains a sequence listing that has been filed in ASCII format through EFS-Web, which is hereby incorporated by reference in its entirety. The ASCII copy was created at 26 months 3 of 2020, named ORN-063PC _ st25.txt and having a size of 139,264 bytes.

Background

Biologics with effector function are a class of biologics with many potential therapeutic applications. In some cases, these biological agents, such as cytokines, encode an effector function when administered to a human that may produce systemic toxicity. Therefore, it is important to maximize the tolerance and therapeutic index of these biological agents in humans so that systemic toxicity in humans or subjects can be reduced.

Often, these biologies need to be delivered to their target(s) in a subject with high precision and in a regulated manner in order for these biologies to be effective. Thus, there is a need for engineered biomolecules that have high intrinsic safety characteristics, are able to reach targets in a subject with high accuracy, and are able to function in a regulated manner.

One example of such a biological agent is a chimeric protein with a signaling agent (with effector function, e.g., a cytokine) attached to a targeting element (capable of finding its target with high accuracy). In these biologies, the signaling agent may be a wild-type signaling agent or a modified signaling agent (e.g., by mutation). The modified signaling agent is generally modified to cause a reduction in the activity of the signaling agent (e.g., substantially reducing its ability to interact/engage with its receptor) in such a way that the effector function of the signaling agent can be restored upon binding of the targeting element to its target (e.g., an antigen on a target cell).

However, such chimeric proteins are suitable for therapeutic use only when certain conditions are met, such as being capable of large-scale production, an in vivo half-life that ensures sufficient exposure to the drug to elicit a therapeutic benefit, an appropriate size to avoid rapid clearance or limited tissue penetration and biodistribution, and other properties that ensure sufficient solubility, stability, and storage characteristics without significant loss of function. Importantly, all or substantially most of the above properties should be achieved without loss of effector function conditionally targeting and maintaining conditional engagement of the modified signaling agent with its receptor. In general, all of these goals are difficult to achieve with chimeric proteins encoded or represented by a single, continuous polypeptide chain. There is a need in the art to achieve such desirable properties of biological agents while maintaining their tolerance and therapeutic index.

Disclosure of Invention

The present technology provides chimeric protein complexes comprising a biological therapeutic agent whose effector function can be delivered to a selected target in a highly precise manner, with limited or no cross-reactivity and limited or no systemic adverse events, while also providing the function of conferring drug properties that enable the production of therapeutic agents (e.g., with sufficient solubility, stability and storage properties) with desirable in vivo exposure times (e.g., half-lives), dimensions (e.g., for biodistribution and clearance characteristics), and large production and/or purification scales for commercial production.

In one aspect, the invention relates to a heterodimeric protein complex and its individual polypeptide chain subunits (components), and wherein the protein complex comprises a targeting moiety that specifically binds to C-type lectin domain family 9 member a (Clec9A), a modified human IFN α 2, and a modified Fc domain.

In one aspect, the present invention relates to a chimeric protein complex comprising: (i) a targeting moiety that specifically binds to C-type lectin domain family 9 member a (Clec9A), (ii) a modified human IFN α 2, and (iii) a modified Fc domain.

In one aspect, the invention relates to a chimeric protein complex, wherein the chimeric protein complex comprises a targeting moiety that specifically binds to C-type lectin domain family 9 member a (Clec9A), a modified human IFN α 2, and a modified Fc domain.

In some embodiments, the chimeric protein complex comprises a polypeptide having at least 95% identity to any one of SEQ ID NOs 1-4 and 43 or at least 98% identity to any one of SEQ ID NOs 1-4 and 43 or at least 99% identity to any one of SEQ ID NOs 1-4 and 43. In some embodiments, the chimeric protein complex comprises a polypeptide of any one of SEQ ID NOs 1-4 and 43, optionally with 0, or 1, or 2, or 3, or 4, or 5 mutations. In some embodiments, the chimeric protein complex comprises a polypeptide of any one of SEQ ID NOs 1-4 and 43.

In some embodiments, the chimeric protein complex comprises a polypeptide incorporating a contiguous amino acid sequence having at least 95% identity to any one of SEQ ID NOs 1-4 and 43 or at least 98% identity to any one of SEQ ID NOs 1-4 and 43.

In another aspect, the present invention relates to a method of treating or preventing cancer, said method comprising administering to a patient in need thereof an effective amount of a chimeric protein complex as disclosed herein.

Another aspect of the invention relates to a pharmaceutical composition comprising a chimeric protein complex as disclosed herein and a pharmaceutically acceptable carrier. In another aspect, the present invention relates to a method for treating or preventing cancer, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition as disclosed herein. In another aspect, the invention relates to a recombinant nucleic acid composition encoding one or more polypeptide chain subunits of the chimeric protein complexes disclosed herein. In another aspect, the invention relates to a host cell comprising a nucleic acid composition encoding one or more chimeric protein complexes disclosed herein.

Drawings

FIG. 1 shows various non-limiting illustrative schematics of chimeric protein complexes of the invention. In various embodiments, each schematic is a composition of the invention. Herein "IFN" refers to the as described herein IFN alpha 2; "VHH" refers to anti-Clec 9AVHH as described herein;is an optional "linker" as described herein; and two long parallel rectangles (one with a protrusion and the other with a depression) are human Fc domains from IgG1, with a knob-into-hole mutation as described herein, and optionally with an effector knockout and/or stabilization mutation also as described herein. Although SEQ ID nos are shown, these are only illustrative, e.g., they will change if a substitution mutation other than R149A is used as described herein.

Figure 2 shows the plasma concentrations of Fc-AFN after intravenous administration in mice. The mean (+ SEM) of 3 individual samples at each time point was plotted.

Figure 3 shows plasma concentrations of CLEC9A AFN (Fc-deficient construct) after intravenous administration in mice. The mean (+ SEM) of 3 individual samples at each time point was plotted.

Figures 4A to 4D show specific binding of CLEC9A-AFN Fc construct to cells expressing human CLEC9A (HL116-hCLEC9a) compared to control cells (HL116 and HEK 293T).

Figure 5 shows tumor growth curves in humanized mice after treatment with buffer or four different CLEC9A-AFN Fc constructs. The mean (mm) of 5 animals at each time point is plotted³)(+SEM)。

Figure 6 shows tumor growth curves in humanized mice after treatment with buffer or increasing doses of a single CLEC9A-AFN Fc construct. The mean (mm) of 5 animals at each time point is plotted³)(+SEM)。

Figure 7 illustrates various divalent orientations and/or configurations contemplated by the present invention. The second VHH moiety that effects bivalent is shaded and forms, together with the linker, the N-or C-terminal extension of the SEQ ID mentioned in the figure. Although SEQ ID nos are shown, these are only illustrative, e.g., they will change if a substitution mutation other than R149A is used as described herein. Further, the VHHs may be identical. The description is described with reference to fig. 1.

FIG. 8A shows the results of phosphorylation of pSTAT1 of IFNa2 in Clec9A-/CD 141-and Clec9A +/CD141+ PBMCs.

FIG. 8B shows the results of pSTAT1 phosphorylation of AFN with A145G or M148A mutations in Clec9A-/CD 141-and Clec9A +/CD141+ PBMC.

Figure 9 shows tumor growth curves in humanized mice after treatment with buffer or 7.5 μ g doses of two different CLEC9A-AFN Fc constructs. Tumor size (mm) was plotted for 6 animals at each time point³) Average value of (+ SEM).

Fig. 10A to 10C show pSTAT1 activity in Clec9A-/CD 141-and Clec9A +/CD141+ PBMCs after treatment with Clec9A targeted AFN with T106O-glycosylation in IFNa2 (fig. 10A) and Clec9A targeted AFN without T106O-glycosylation in IFNa2 (fig. 10B) and untargeted variants (fig. 10C).

Figure 11 shows the antitumor activity of Clec9A targeted AFN Fc with the a145G mutation of IFN α 2.

Detailed Description

In one aspect, the invention relates to a chimeric protein complex, wherein the chimeric protein complex comprises a targeting moiety that specifically binds to C-type lectin domain family 9 member a (Clec9A), a modified human IFN α 2, and a modified Fc domain. In various embodiments, the chimeric protein complex comprises a polypeptide having at least 95% identity to any one of SEQ ID NOs 1-4 and 43. In various embodiments, the chimeric protein complex comprises a polypeptide having at least 98% identity to any one of SEQ ID NOs 1-4 and 43 or at least 99% identity to any one of SEQ ID NOs 1-4 and 43. In various embodiments, the chimeric protein complex comprises the polypeptides of SEQ ID NOs 1-4 and 43, wherein the sequence has fewer than 10 mutations compared to the selected sequence. In various embodiments, the chimeric protein complex comprises the polypeptides of SEQ ID NOs 1-4 and 43, wherein the sequence has fewer than 5 mutations compared to the selected sequence.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 1. This sequence includes a single domain antibody (VHH) against Clec9A (i.e., R1CHCl50(opt4)), a linker (i.e., 5 × GGS), and an Fc pore Ridgway sequence with a LALA-KQ mutation (i.e., Fc pore Ridgway (LALA-KQ), see Ridgway et al, Protein Engineering 1996; 9:617-621, which is incorporated by reference in its entirety). Such a construct having the sequence SEQ ID NO 1 is represented as follows: variant 1VHH-Fc R1CHCL50(opt4) -5 x GGS-Fc pore Ridgway (LALA-KQ).

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 2. This sequence includes a single domain antibody (VHH) against Clec9A (i.e., R1CHCl50(opt4)), a linker (i.e., 5 × GGS), and an Fc pore Merchant sequence with a LALA-KQ mutation (i.e., Fc pore Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-. Such a construct having SEQ ID NO 2 is represented as follows: VHH-Fc: r1CHCl50(opt4) -5 GGS-Fc pore Merchant (LALA-KQ).

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 3. This sequence includes a single domain antibody (VHH) against Clec9A (i.e., 3LEC89(opt4)), a linker (i.e., 5 × GGS), and an Fc pore Ridgway sequence with a LALA-KQ mutation (i.e., Fc pore Ridgway (LALA-KQ), see Ridgway et al, Protein Engineering 1996; 9:617-621, which is incorporated by reference in its entirety). Such a construct having SEQ ID NO 3 is represented as follows: VHH-Fc: 3LEC89(opt4) -5 × GGS-Fc pore Ridgway (LALA-KQ).

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 4. This sequence includes a single domain antibody (VHH) against Clec9A (i.e., 3LEC89(opt4)), a linker (i.e., 5 × GGS), and an Fc pore Merchant sequence with a LALA-KQ mutation (i.e., Fc pore Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-Achan 681, which is incorporated by reference in its entirety). Such a construct having SEQ ID NO 4 is represented as follows: VHH-Fc: 3LEC89(opt4) -5 GGS-Fc pore Merchant (LALA-KQ).

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 43. This sequence includes a single domain antibody (VHH) against Clec9A (i.e., R1CHCl50(opt4)), a linker (i.e., 5 × GGS), and an Fc pore Merchant sequence with a LALA-KQ mutation and no C-terminal lysine (i.e., Fc pore Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-.

Chimeric protein complexes of the invention may also include amino acid sequences that are at least 95% identical to any of SEQ ID NOs 5-8, 29-36, or 41-42. In various embodiments, the chimeric protein complex comprises a polypeptide having an amino acid sequence at least 98% identical to any of SEQ ID NOs 5-8, 29-36, or 41-42, or at least 99% identical to any of SEQ ID NOs 5-8, 29-36, or 41-42. In various embodiments, the chimeric protein complex comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs 5-8, 29-36, or 41-42, wherein the sequence has fewer than 10 mutations compared to the selected sequence. In various embodiments, the chimeric protein complex comprises a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs 5-8, 29-36, or 41-42, wherein the sequence has fewer than 5 mutations compared to the selected sequence.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 5. This sequence includes a modified human interferon alpha 2b with the R149A mutation (i.e., huIFNa 2B-R149A), a linker (i.e., 10 × GGS-G), and an Fc knob Ridgway sequence with the LALA-KQ mutation (i.e., Fc knob Ridgway (LALA-KQ), see Ridgway et al, Protein Engineering 1996; 9:617-621, which is incorporated by reference in its entirety). Such a construct having the sequence of SEQ ID NO 5 is represented as follows: variant 1 Fc-AFN: fc knob Ridgway (LALA-KQ) -10 GGS-G-huIFNa2B _ R149A.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 6. This sequence includes a modified human interferon alpha 2b with mutations R149A and T106E (i.e., huIFNa 2B-R149A-T106E), a linker (i.e., 10 × GGS-G), and an Fc knob Ridgway sequence with a LALA-KQ mutation (i.e., Fc knob Ridgway (LALA-KQ), see Ridgway et al, Protein Engineering 1996; 9: 617-. Such a construct having the sequence of SEQ ID NO 6 is represented as follows: variant 2 Fc-AFN: fc knob Ridgway (LALA-KQ) -10 × GGS-G-huIFNa2B _ R149A _ T106E.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 7. This sequence includes a modified human interferon alpha 2b with the R149A mutation (i.e., huIFNa 2B-R149A), a linker (i.e., 10 × GGS-G), and an Fc knob Merchant sequence with the LALA-KQ mutation (i.e., Fc knob Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-. Such a construct having the sequence of SEQ ID NO 7 is represented as follows: variant 3 Fc-AFN: fc knob Merchant (LALA-KQ) -10 × GGS-G-huIFNa2B _ R149A.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 8. This sequence includes a modified human interferon alpha 2b with mutations R149A and T106E (i.e., huIFNa 2B-R149A-T106E), a linker (i.e., 10 × GGS-G), and an Fc knob Merchant sequence with a LALA-KQ mutation (i.e., Fc knob Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-. Such a construct having the sequence of SEQ ID NO 8 is represented as follows: variant 4 Fc-AFN: fc knob Merchant (LALA-KQ) -10 × GGS-G-huIFNa2B _ R149A _ T106E.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO 41. This sequence includes a modified interferon alpha 2b with the A145G mutation, a linker (i.e., 10-GGS-G), and the Fc knob Merchant sequence with the LALA-KQ mutation (i.e., Fc knob Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-. Such a construct having the sequence SEQ ID NO 41 is represented as follows: fc 4' -IFNa2b _ A145G.

In various embodiments, the chimeric protein complex comprises a polypeptide having the amino acid sequence SEQ ID NO 42. This sequence includes a modified interferon alpha 2b with mutations T106A and A145G, a linker (i.e., 10 × GGS-G), and an Fc knob Merchant sequence with a LALA-KQ mutation (i.e., Fc knob Merchant (LALA-KQ), see Merchant et al, Nature Biotechnology 1998; 16: 677-. Such a construct having the sequence SEQ ID NO 42 is represented as follows: fc 4' -IFNa2a _ T106E _ A145G.

In one embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 95% identity to any of SEQ ID NO:1 or 3 and (ii) an amino acid sequence having at least 95% identity to any of SEQ ID NO:5 or 6. In another embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 98% identity to any of SEQ ID NO 1 or 3 and (ii) an amino acid sequence having at least 98% identity to any of SEQ ID NO 5 or 6. In another embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 99% identity to any of SEQ ID NO:1 or 3 and (ii) an amino acid sequence having at least 99% identity to any of SEQ ID NO:5 or 6. In one embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 95% identity to any of SEQ ID NOs 2 or 4 and (ii) an amino acid sequence having at least 95% identity to any of SEQ ID NOs 7 or 8. In one embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 98% identity to any of SEQ ID NO 2 or 4 and (ii) an amino acid sequence having at least 98% identity to any of SEQ ID NO 7 or 8. In another embodiment, the chimeric protein complex comprises: (i) an amino acid sequence having at least 99% identity to any of SEQ ID NOs 2 or 4 and (ii) an amino acid sequence having at least 99% identity to any of SEQ ID NOs 7 or 8.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence at least 95% identical to either of SEQ ID nos. 31 or 32. In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to either of SEQ ID NOs 31 or 32. In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to either of SEQ ID NOs 31 or 32. In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:43 and (ii) a polypeptide having an amino acid sequence at least 95% identical to either of SEQ ID NOs 41 or 42. In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID No. 43 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to either of SEQ ID NOs 41 or 42. In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID No. 43 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to either of SEQ ID NOs 41 or 42.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NOs 1 or 3 and (ii) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NOs 5 or 6.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NOs 1 or 3 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NOs 5 or 6.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NOs 1 or 3 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NOs 5 or 6.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NOs 2 or 4 and (ii) a polypeptide having an amino acid sequence at least 95% identical to any of SEQ ID NOs 7 or 8.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NOs 2 or 4 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to any of SEQ ID NOs 7 or 8.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NOs 2 or 4 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to any of SEQ ID NOs 7 or 8.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence at least 95% identical to either of SEQ ID nos. 31 or 32.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to either of SEQ ID NOs 31 or 32.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID No. 2 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to either of SEQ ID NOs 31 or 32.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO:43 and (ii) a polypeptide having an amino acid sequence at least 95% identical to either of SEQ ID NOs 41 or 42.

In various embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 98% identity to SEQ ID No. 43 and (ii) a polypeptide having an amino acid sequence with at least 98% identity to either of SEQ ID NOs 41 or 42.

In some embodiments, the chimeric protein complex comprises: (i) a polypeptide having an amino acid sequence with at least 99% identity to SEQ ID No. 43 and (ii) a polypeptide having an amino acid sequence with at least 99% identity to either of SEQ ID NOs 41 or 42.

In some embodiments, the present invention relates to a multivalent or bivalent chimeric protein complex comprising: a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 17 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 7; a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 2 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 19; a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 18 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 7; a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 20 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence of SEQ ID NO 7; polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 2 and polypeptides having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 22; or a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 21 and a polypeptide having a sequence at least 95%, or 97%, or 98%, or 99% identical to the amino acid sequence SEQ ID NO 7. In some embodiments, the present invention relates to a method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a multivalent or bivalent chimeric protein complex described herein.

In some embodiments, the present invention relates to a chimeric protein complex comprising at least two polypeptides having a sequence at least 95%, or 97%, or 98%, or 99%, or 100% identical to the amino acid sequence of any one of SEQ ID nos 1-43. In various embodiments, the present invention relates to a method for treating or preventing cancer, comprising administering to a patient in need thereof an effective amount of a chimeric protein complex comprising at least two polypeptides having a sequence at least 95%, or 97%, or 98%, or 99%, or 100% identical to the amino acid sequence of any one of SEQ ID nos. 1-43.

In some embodiments, the chimeric protein complex comprises a modified human interferon alpha 2. In various embodiments, the modified IFN- α 2 agent has reduced affinity and/or activity for an IFN- α/β receptor (IFNAR), i.e., IFNAR1 and/or IFNAR2 chain. In some embodiments, the modified IFN- α 2 agent has substantially reduced or eliminated affinity and/or activity for IFN- α/β receptor (IFNAR), i.e., IFNAR1 and/or IFNAR2 chains. In some embodiments, a modified human interferon alpha 2 as disclosed herein has an amino acid sequence with at least 95% identity to SEQ ID NO 9 or 10. In other embodiments, the modified human IFN alpha 2 and SEQ ID NO 9 or 10 with at least 98% or at least 99% of the same amino acid sequence. In some embodiments, the modified human IFN alpha 2 relative to the amino acid sequence of SEQ ID NO. 9 or 10, has 1-3 mutations. In one embodiment, relative to SEQ ID NO:9 or 10, the modified human IFN alpha 2 contains R149A mutation. In one embodiment, relative to SEQ ID NO:9 or 10, the modified human IFN alpha 2 contains A145G mutation.

In some embodiments, the targeting moiety of the chimeric protein complexes disclosed herein comprises a recombinant heavy chain-only antibody (VHH). In some embodiments, the VHH has an amino acid sequence with at least 95% identity to one of SEQ ID NOs 11 or 12. In other embodiments, the VHH comprises an amino acid sequence having at least 98% identity to one of SEQ ID NOs 11 or 12 or at least 99% identity to one of SEQ ID NOs 11 or 12. In some embodiments, the VHH has the amino acid sequence of any one of SEQ ID NOs 11 and 12.

In some embodiments, the chimeric protein complexes disclosed herein comprise two targeting moieties. In some embodiments, the chimeric protein complexes disclosed herein comprise two identical targeting moieties. In various embodiments, the orientation of these divalent modes is as shown in fig. 7.

In some embodiments, the chimeric protein complexes disclosed herein comprise two targeting moieties. In some embodiments, the chimeric protein complexes disclosed herein comprise two different targeting moieties. In various embodiments, the orientation of these divalent modes is as shown in fig. 7. For example, in some embodiments, the chimeric protein complexes disclosed herein comprise targeting moieties (but not limited to VHH) to Clec9A and PD-L1.

In various embodiments, the R149A mutation is present in IFN- α 2.

In various embodiments, the R149A mutation is not present in IFN- α 2, but rather is present in another mutation. For example, such a substitution mutation may be at one of positions R33, R144, a145, M148, and L153. In various embodiments, the substitution mutation is one of R33A, R144A, R144I, R144L, R144S, R144T, R144Y, a145D, a145G, a145H, a145K, a145Y, M148A, and L153A. For clarity, any reference herein to R149A may be replaced by one of R33A, R144A, R144I, R144L, R144S, R144T, R144Y, a145D, a145G, a145H, a145K, a145Y, M148A, and L153A in various embodiments. In various embodiments, any reference herein to R149A may be substituted for a 145G.

In some embodiments, the chimeric protein complexes disclosed herein comprise at least one Fc domain. In some embodiments, the chimeric protein complex comprises a modified Fc domain, wherein the modified Fc domain comprises one or more of the following mutations relative to any one of SEQ ID NOs 13-16: P329G, K322Q, K322A or P331S. In other embodiments, the modified Fc domain comprises one or more of the following mutations relative to human IgG1 Fc: P329G, K322Q, K322A or P331S.

In some embodiments, the chimeric protein complex comprises a modified Fc domain having an amino acid sequence with at least 90% identity to SEQ ID NOs 13-16. In other embodiments, the modified Fc domain has an amino acid sequence with at least 93% identity to SEQ ID NOs 13-16. In other embodiments, the modified Fc domain has an amino acid sequence that is at least 95% identical to SEQ ID NOs 13-16.

In another aspect, the present invention relates to a method of treating or preventing cancer, said method comprising administering to a patient in need thereof an effective amount of a chimeric protein complex as disclosed herein. The methods may be used to treat or prevent cancer selected from one or more of: basal cell carcinoma; biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancers; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancers of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); a glioblastoma; liver cancer; hepatoma; an intraepithelial neoplasm; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); melanoma; a myeloma cell; neuroblastoma; oral cancer (lip, tongue, mouth and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland cancer; sarcomas (e.g., kaposi's sarcoma); skin cancer; squamous cell carcinoma; gastric cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas, including hodgkin's and non-hodgkin's lymphomas, and B-cell lymphomas (including low grade/follicular non-hodgkin's lymphomas (NHLs); small Lymphocytic (SL) NHL; intermediate/follicular NHL; intermediate diffuse NHL; higher-grade immunocytogenic NHL; higher lymphoblastic NHL; high-grade small non-nucleated cell NHL; giant-mass NHL; mantle cell lymphoma; AIDS-related lymphomas; and waldenstrom's macroglobulinemia; chronic Lymphocytic Leukemia (CLL); acute Lymphoblastic Leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), and abnormal vascular proliferation associated with nevus maculatus hamartoma; edema (e.g., edema associated with brain tumors); and megs syndrome.

Another aspect of the invention relates to a pharmaceutical composition comprising a chimeric protein complex as disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the invention relates to pharmaceutical compositions comprising the chimeric protein complexes of the invention.

Another aspect of the present invention relates to a method for treating or preventing cancer, said method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition as disclosed herein. The pharmaceutical composition may be used for treating or preventing a cancer selected from one or more of: basal cell carcinoma; biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancers; breast cancer; peritoneal cancer; cervical cancer; choriocarcinoma; colon and rectal cancer; connective tissue cancer; cancers of the digestive system; endometrial cancer; esophageal cancer; eye cancer; head and neck cancer; gastric cancer (including gastrointestinal cancer); a glioblastoma; liver cancer; hepatoma; an intraepithelial neoplasm; kidney or renal cancer; laryngeal cancer; leukemia; liver cancer; lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma); melanoma; a myeloma cell; neuroblastoma; oral cancer (lip, tongue, mouth and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland cancer; sarcomas (e.g., kaposi's sarcoma); skin cancer; squamous cell carcinoma; gastric cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulvar cancer; lymphomas, including hodgkin's and non-hodgkin's lymphomas, and B-cell lymphomas (including low grade/follicular non-hodgkin's lymphomas (NHLs); small Lymphocytic (SL) NHL; intermediate/follicular NHL; intermediate diffuse NHL; higher-grade immunocytogenic NHL; higher lymphoblastic NHL; high-grade small non-nucleated cell NHL; giant-mass NHL; mantle cell lymphoma; AIDS-related lymphomas; and waldenstrom's macroglobulinemia; chronic Lymphocytic Leukemia (CLL); acute Lymphoblastic Leukemia (ALL); hairy cell leukemia; chronic myeloblastic leukemia; and other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), and abnormal vascular proliferation associated with nevus maculatus hamartoma; edema (e.g., edema associated with brain tumors); and megs syndrome.

In another aspect, the invention relates to a recombinant nucleic acid composition encoding one or more chimeric protein complexes disclosed herein, e.g., encoding the entire chimeric protein complex or a constituent polypeptide thereof. In another aspect, the invention relates to a host cell comprising a recombinant nucleic acid composition complex disclosed herein.

Definition of

As used herein, "a/an" or "the" may mean one or more than one.

Furthermore, the term "about" when used in conjunction with a numerical indication of a reference means that the referenced numerical indication adds or subtracts up to 10% of the referenced numerical indication. For example, the language "about 50" covers the range of 45 to 55.

As used herein, the term "effective amount" refers to an amount sufficient to achieve a desired therapeutic and/or prophylactic effect, e.g., an amount such that a disease or disorder or one or more signs or symptoms associated with a disease or disorder is prevented or reduced. In the case of therapeutic or prophylactic use, the amount of the composition administered to a subject will depend on the extent, type and severity of the disease, as well as the characteristics of the individual (such as general health, age, sex, weight and drug resistance). The skilled person will be able to determine the appropriate dosage in view of these and other factors. The compositions may also be administered in combination with one or more other therapeutic compounds. In the methods described herein, the therapeutic compound may be administered to a subject suffering from one or more signs or symptoms of a disease or disorder. As used herein, a property is "reduced" if the readout of activity and/or effect is reduced by a significant amount, such as by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or more, up to and including at least about 100%, in the presence of an agent or stimulus relative to the absence of such modulation. As will be appreciated by one of ordinary skill in the art, in some embodiments, the activity is reduced and some downstream readouts will be reduced but other downstream readouts may be increased.

Conversely, an activity is "increased" if the readout of activity and/or effect is increased by a significant amount, e.g., by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, at least about 98% or more, up to and including at least about 100% or more, at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 6-fold, at least about 7-fold, at least about 8-fold, at least about 9-fold, at least about 10-fold, at least about 50-fold, at least about 100-fold in the presence of an agent or stimulus relative to the absence of such agent or stimulus.

Although the open-ended term "comprising" is used herein as a term such as comprising, containing, or having synonyms for describing and claiming the present invention, the invention or embodiments thereof may alternatively be described using alternative terms such as "consisting of … …" or "consisting essentially of … …".

The amount of the compositions described herein required to achieve a therapeutic effect can be determined empirically for a particular purpose according to routine procedures. Generally, for administration of a therapeutic agent for therapeutic purposes, the therapeutic agent is administered in a pharmacologically effective dose. "pharmacologically effective amount," "pharmacologically effective dose," "therapeutically effective amount," or "effective amount" refers to an amount sufficient to produce a desired physiological effect or to achieve a desired result, particularly for the treatment of a disorder or disease. As used herein, an effective amount will include an amount sufficient to, for example, delay the development of, alter the course of (e.g., slow the progression of), reduce or eliminate one or more symptoms or manifestations of a disorder or disease, and reverse the symptoms of a disorder or disease. Therapeutic benefit also includes interrupting or slowing the progression of the underlying disease or condition, regardless of whether an improvement is achieved.

As used herein, "method of treatment" is equally applicable to the use of a composition for the treatment of a disease or condition described herein and/or to one or more uses of a composition for the manufacture of a medicament for the treatment of a disease or condition described herein.

As used herein, Fc domain mutations are numbered according to the EU convention (Edelman et al, PNAS 1969; 63(1)78-85, which is incorporated by reference in its entirety). As used herein, the term "LALA" mutation refers to a double mutant Fc domain having the L234A mutation and the L235A mutation. As used herein, the term "KQ" mutation refers to a mutant Fc domain having the K322Q mutation.

Knob-hole mutants are Ridgway et al, Protein Engineering 1996; 9:617-621 (which is incorporated by reference in its entirety), namely Y407T/T366Y.

Alternatively, the knob-hole-in-mutant is Merchant et al, Nature Biotechnology 1998; 16: 677-.

Unless otherwise indicated, Fc is from human IgG 1.

Sequence of

1 variant 1VHH-Fc of SEQ ID NO: r1CHCl50(opt4) -5 × GGS-Fc pore Ridgway (LALA-KQ)

2 variant 2 VHH-Fc of SEQ ID NO: r1CHCl50(opt4) -5 GGS-Fc pore Merchant (LALA-KQ)

3 variant 3 VHH-Fc of SEQ ID NO: 3LEC89(opt4) -5 × GGS-Fc hole Ridgway (LALA-KQ)

D

4 variant 4VHH-Fc of SEQ ID NO: 3LEC89(opt4) -5 GGS-Fc pore Merchant (LALA-KQ)

5 variant 1 Fc-AFN: fc knob Ridgway (LALA-KQ) -10 GGS-G-huIFNa2B _ R149A

6 variant 2 Fc-AFN: fc knob Ridgway (LALA-KQ) -10 × GGS-G-huIFNa2B _ R149A _ T106E

7 variant 3 Fc-AFN: fc knob Merchant (LALA-KQ) -10 GGS-G-huIFNa2B _ R149A

8 variant 4 Fc-AFN: fc knob Merchant (LALA-KQ) -10 GGS-G-huIFNa2B _ R149A _ T106E

SEQ ID NO 9 human IFN alpha 2a (amino acid sequence)

SEQ ID NO 10 human IFN alpha 2b (amino acid sequence)

SEQ ID NO 11R1CHCl50_ opt4 (anti-human Clec9a VHH)

SEQ ID NO 123 LEC89_ opt4 (anti-human Clec9a VHH)

Amino acid sequence of SEQ ID NO 13Fc (human IgG1) -having LALA mutation and Ridgway pore

Amino acid sequence of SEQ ID NO 14Fc (human IgG1) -having LALA mutation and Ridgway knob

Amino acid sequence of SEQ ID NO 15Fc (human IgG1) -having LALA mutation and Merchant pore

Amino acid sequence of SEQ ID NO 16Fc (human IgG1) -having LALA mutation and Merchant knob

Other sequences are identified elsewhere in the text.

Examples

In some embodiments, two variations of the knob-into-hole technique are used: ridgway (from Ridgway et al, Protein Engineering 1996; 9: 617. sup. 621) and Merchant (from Merchant et al, Nature Biotechnology 1998; 16: 677. sup. 681).

The "standard" effector mutation in the Ridgway construct was LALA-PG (P329G), which is described herein. The "standard" effector mutation in the Merchant construct was LALA-KQ (K322Q), as described herein.

The term "actaferon (afn)" or "actakinene" is occasionally used herein to refer to the chimeric proteins described herein (detailed information on the form of the chimeric protein is provided in the examples).

Example 1 Fc-based AcTaferon

To increase the half-life of CLEC 9A-specific (CLEC9A is a highly specific cDC1 marker) AcTaferon, the human CLEC9A-VHH _ huIFNa2 fusion protein was converted to an Fc fusion. For this, human IgG1-Fc was fused to AcTaferon via a 20 × GGS linker (VHH 3LEC89-20 × GGS-huIFNa2_ R149). In a second version, the Fc domain is constructed between the VHH and IFN moieties. The effector function of human IgG1-Fc was reduced by introducing the LALA-P329G mutation.

Relevant sequences for expression in mammalian cells are:

p-956 pcDNA3.4-mouse light chain kappa-hIgG 1-LALA-PG-20 × GGS-3LEC89-20*GGS+G-IFNa2 R149A

P-957 pcDNA3.4-mouse Ig heavy chain-3LEC89-20*GGS-hIgG1-LALA-PG-20*GGS+G-IFNa2 R149A

These constructs were prepared by geneart (Thermo Fisher) and were transiently expressed in the ExpiCHO expression system (Thermo Fisher) according to the manufacturer's instructions. Ten days after transfection, supernatants were collected and cells were removed by centrifugation. Recombinant proteins were purified from the culture medium using rProtein a Sepharose Fast Flow resin (GE Healthcare) according to the manufacturer's instructions. Unexpectedly, proteins expressed at 70-170mg/L showed severe solubility problems, even at concentrations below 1mg/ml, they tended to aggregate and precipitate when stored at 4 ℃ or after a single freeze-thaw cycle. Similar observations indicate that Fc-based AcTakine format is manufacturable when VHH 3LEC89 is replaced with unrelated VHH 2LIG99 specific for human PD-L1.

Surprisingly, the solubility problem was solved by designing different types of Fc constructs. In this novel form, heterodimeric Fc complexes were generated by binding VHH-Fc fusions to Fc-IFN fusions using knob-in-hole mutations Y407T/T366Y or S354C: T366W/Y349C: T366S: L368A: Y407V. Other variants include selective knock-out of the O-glycosylation site in huIFNa2 by mutation of T106E. A total of 8 constructs were designed based on 2 different humanized CLEC9A specific VHHs. In order to reduce the effector function of the IgG1-Fc protein, the mutation LALA-K322Q was used. The sequence of the mature protein is represented by SEQ ID NO 1-8. This resulted in a total of 8 different Fc complexes that could be generated by combining knob and hole structures as shown in figure 1.

For expression in mammalian cells, the sequences were ligated to leader sequences and constructs were prepared by geneart (thermo fisher). Production was carried out in expihho cells as described above. The recombinant Protein was purified from the supernatant on a HiTrap Protein a HP (GE Healthcare), and after neutralization the eluted Protein was desalted on a G25 column (GE Healthcare) followed by a final 0.22 μm filtration. The protein appears to remain soluble at a concentration of at least 10mg/mL at 4 ℃ or after repeated freeze/thaw cycles.

Example 2 PK Effect of chimeras with and without Fc

PK (pharmacokinetic) studies in mice were performed using 4 different variants of the Fc protein based on R1CHCL 50.

A total of 9 mice were given 1mg/kg of each construct intravenously. Blood was drawn from the first group of 3 mice at 5 minutes, 8 hours and 6 days, from the second group of 3 mice at 15 minutes, 1 day and 10 days, and from the third group of 3 mice at 2 hours, 3 days and 14 days. The concentration of intact CLEC9A-AFN Fc was measured by ELISA. Briefly, a MAXISORP Nunc immune plate (Thermo Scientific) was coated overnight with 0.5. mu.g/ml anti-human interferon alpha mAb (clone MMHA-13; PBL Assay Science) in PBS. After washing the plates four times with PBS + 0.05% Tween-20, blocking with 0.1% casein in PBS for at least 1 hour at room temperature. Subsequently, the diluted samples and standards were incubated in 0.1% casein in PBS for 2 hours at room temperature. After another wash cycle, the custom-made rabbit anti-VHH (diluted 1/20000 in 0.1% casein PBS) was incubated for 2 hours at room temperature, followed by another wash cycle and incubated with HRP-conjugated goat anti-rabbit (Jackson-111. 035. sup. 144; 1:5000, 0.1% casein) for 1 hour at room temperature. After the last washing cycle, peroxidase activity was measured using KPL substrate (5120-0047; SeraCare) according to the manufacturer's instructions. The concentration in the sample was calculated using GraphPad Prism. The measured concentrations are plotted in figure 2 and show that all 4 constructs have similar PK profiles, except that at the last sampling time point, the rate of clearance of the Ridgway based Fc construct was faster. It is estimated that the terminal half-life of the Ridgway construct averages about 3 days, while the terminal half-life of the Merchant construct averages about 4.5 days.

PK studies in mice using CLEC9A AcTaferon without Fc fusion.

In a separate study, the PK of Fc-free AFN (3LEC89-20 × GGS-huIFNa2_ R149A-his6) in mice was evaluated. The sequence of the chimera is:

p-602 sequence

Nine animals were dosed intravenously at 3 mg/kg. Blood was drawn from the first group of 3 mice at 5 minutes and 1 hour, from the second group of 3 mice at 15 minutes and 3 hours, and finally from the last group at 8 hours. The concentrations in plasma samples were measured using the same ELISA as described for the Fc fusion protein. The measured concentration (fig. 3) shows a rapid clearance of this type of molecule, resulting in a concentration below the detection limit (0.12 μ g/ml) at the 8 hour time point. The estimated terminal half-life is in the range of only 2 hours, clearly demonstrating the superior half-life properties of Fc-based AcTakine.

Example 3 binding of constructs and in vivo Effect

To measure relative binding affinity, the same 4 molecules as shown in example 2 were incubated with serially diluted CLEC9A-AFN Fc constructs on HL116-hClec9A cells. To assess binding specificity, parental HL116 cells and parental HEK293T cells (both lacking detectable Clec9A expression) were also incubated with the same serially diluted Clec9A-AFN Fc construct. Binding was detected by subsequent incubation with FITC-conjugated anti-human secondary Ab, measured on a MACSQuant X instrument (Miltenyi Biotech) and analyzed using FlowLogic software (Miltenyi Biotech). The data in fig. 4 shows that Fc-based AFN has similar binding EC50 to HL116-hClec9A cells, while no binding was detected on cell lines that do not express Clec 9A.

To assess the efficacy of Fc-based AFN, these molecules were tested in a tumor model in humanized mice. Briefly, neonatal NSG mice (1-2 days old) were sub-lethally irradiated with 100cGy and then delivered intrahepatically 1x10⁵Individual CD34+ human stem cells (from HLA-a2 positive cord blood). Mice were inoculated subcutaneously with 25x10 at week 13 post stem cell transfer⁵Human RL follicular lymphoma cells (ATCC CRL-2261; insensitive to the direct antiproliferative effects of IFN). Mice were treated intraperitoneally with 30 μ g of human Flt3L protein daily from day 10 to day 19 after tumor inoculation. On day 11 post tumor inoculation, when palpable tumors were visible, i.v. injections of buffer or Fc-AFN (8 or 75 μ g) were started once a week (n-5 mice/group). Evaluation of tumor size (Caliper measurement), body Each dayWeight and temperature. The data in fig. 5 and 6 show tumor growth up to 6 days after the second treatment. Figure 5 shows that all constructs induced similar levels of tumor growth inhibition at the lower 8 μ g dose. Figure 6 shows the results of higher doses of Merchant construct resulting in increased tumor growth inhibition. The body weight and temperature data did not show any significant difference between buffer treatment and AFN treatment, confirming that all AFN treatments were well tolerated.

Example 4 bivalent and bispecific variants

To further enhance the targeting ability of the molecule, additional VHH moieties were added to create constructs, a non-limiting example of which is shown in figure 7. These novel constructs target CLEC9A in a bivalent pattern or both CLEC9A and PD-L1, for example. As an example, the following constructs are based on R1CHCL50(opt4) VHH against CLEC9A and/or 2LIG99 VHH against PD-L1 and huIFNa2B _ R149A. A similar series can be generated by replacing R1CHCL50(opt4) with 3LEC89(opt 4). Alternatively, huIFNa2B _ R149A may be replaced with huIFNa2B _ R149A _ T106E. Finally, the following example is based on an Fc part containing Merchant-based knob-in-hole mutations, which can be exchanged with an Fc part with Ridgway-based knob-in-hole mutations.

Novel construct

Bivalent CLEC 9A-targeted pore chain of additional VHH at the N-terminus of fc (Merchant)

VHH-VHH-Fc：R1CHCL50(opt4)-5＊GGS-R1CHCL50(opt4)-5＊GGS-Fc(LALA-KQ)

Bivalent CLEC 9A-targeted pore chain of additional VHHs at the C-terminus of Fc (Merchant)

VHH-Fc-VHH:R1CHCL50(opt4)-5＊GGS-Fc(LALA-KQ)-5＊GGS-R1CHCL50(opt4)

Bivalent CLEC9A targeted knob chain of N-terminal additional VHH of fc (Merchant)

VHH-Fc-AFN：R1CHCL50(opt4)-5＊GGS-Fc(LALA-KQ)-10＊GGS-G-hulFNa2B_R149A

Bispecific CLEC9A-PDL1 targeted pore chains of N-terminal additional VHHs of Fc (Merchant)

VHH-VHH-Fc：2LIG99-5＊GGS-R1CHCL50(opt4)-5＊GGS-Fc(LALA-KQ)

Bispecific CLEC9A-PD-L1 Targeted pore chain of additional VHH C-terminal of E.Fc (Merchant)

VHH-Fc-VHH：R1CHCL50(opt4)-5＊GGS-Fc(LALA-KQ)-5＊GGS-2LIG99

Bispecific CLEC9A-PD-L1 Targeted knob chain of additional VHH at the N-terminus of Fc (Merchant)

VHH-Fc-AFN：2LIG99-5＊GGS-Fc(LALA-KQ)-10＊GGS-G-hulFNa2B_R149A

For expression in mammalian cells, the sequences were ligated to leader sequences and expression constructs were prepared by geneart (thermo fisher). Production was carried out in expihho cells as described above. The recombinant Protein was purified from the supernatant on a HiTrap Protein a HP (GE Healthcare), and after neutralization the eluted Protein was desalted on a G25 column (GE Healthcare) followed by a final 0.22 μm filtration. More specifically, the following expression constructs were combined to produce an Fc-based AcTaferon.

The construct containing SEQ ID NO 17 + the construct containing SEQ ID NO 7

The construct containing SEQ ID NO 2 + the construct containing SEQ ID NO 19

Construct containing SEQ ID NO. 18 + construct containing SEQ ID NO. 7

Construct containing SEQ ID NO. 20 + construct containing SEQ ID NO. 7

Construct containing SEQ ID NO 2 + construct containing SEQ ID NO 22

Construct containing SEQ ID NO 21 + construct containing SEQ ID NO 7

Example 5A 145G and M148A AFN mutations

In this example, the potential of IFN variants a145G and M148A as AFN mutations (i.e., warhead mutations that result in loss of biological activity that can be recovered after targeting the warhead) was evaluated.

Mutations were evaluated in the context of "knob-in-hole" Fc AFN of heterodimers. Here, the Clec9A VHH R1CHCL50 sequence was fused via a flexible 20 x GGS linker and in pcdna3.4 expression vector to a human IgG 1Fc sequence containing L234A _ L235A _ K322Q effector mutations and a "pore" modification Y349C _ T366S _ L368A _ Y407V (see sequence R1CHCL50-Fc3 below). The second AFN partner (also cloned into pcdna3.4 vector), consisting of a fusion between the Fc sequence of human IgG1 containing L234A _ L235A _ K322Q effector mutation and the "knob" modification S354C _ T366W and the hIFNa2 sequence with AFN mutation a145G or M148A and O-glycosylation mutation T106E (see sequence below).

To generate these "knob-in-hole" Fc AFNs, a combination of "hole" and "knob" plasmids was transfected into expihcho according to the manufacturer's instructions^TMIn cells (ThermoFisher). Seven days after transfection, recombinant proteins were purified using a protein a rotating plate (ThermoFisher), quantified, and purity tested using SDS-PAGE.

STAT1 phosphorylation of the resulting a145G and M148 AFN was tested in primary cDC1 cells (expressing Clec9A, a target of AFN) compared to other PBMC populations. In short, useLymphoprep^TM(StemCell technologies) density gradient centrifugation was performed to separate PBMCs from buffy coats of healthy donors. Cells were washed twice with FACS buffer (2% FBS, PBS of 1mM EDTA) and stained with anti-Clec 9A and anti-CD 141 Ab (both from Miltenyi) for 20 min at 4 ℃ to identify the cDC1 population. After two washes, cells were stimulated with serial dilutions of wild-type IFNa2 or both AFNs for 15 min at 37 ℃. After fixation (10 min, 37 ℃, fixation buffer I; BD Biosciences), permeabilization (30 min, on ice, Perm III buffer I; BD Biosciences), and washing, cells were stained with anti-STAT 1 pY701 ab (BD Biosciences). Use ofSample collection on X instrument (Miltenyi Biotec) and use of FlowLogic^TMThe software (Miltenyi Biotec) performed the analysis. The data in fig. 8A-8B clearly demonstrate that (i) Clec9A-/CD 141-and Clec9A +/CD141+ cells were equally sensitive to wild-type IFNa2, and (ii) both the a145G and M148A mutations abolished most of the signaling in non-cDC 1 PBMC (Clec9A-/CD141-), but targeting Clec9A positive cells (Clec9A +/CD141+) restored this signaling to a large extent. This resulted in at least a 100-fold improvement in the AFN effect of the a145G or M148A mutations and demonstrated the potential of these mutations in AFN design.

The sequence is as follows:

P-1451：20H GGS-hlgG 1Fc _ L234A _ L235A _ K322Q _ Y349C _ T366S _ L368A _ Y407V (abbreviation: R1CHCL50-Fc3)

P-1846：hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-20＊GGS-

(abbreviation: Fc4-hlFNa2_ A145G)

P-1850：hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-20＊GGS-

(abbreviation: Fc4-hlFNa2_ M148A)

Example 6: in vivo A145G and M148A AFN mutations

To assess the efficacy of Fc-based AFN, these molecules were tested in a tumor model in humanized mice. Briefly, neonatal NSG mice (1-2 days old) were sub-lethally irradiated with 100cGy and then delivered intrahepatically 1x10⁵Individual CD34+ human stem cells (from HLA-a2 positive cord blood). Mice were inoculated subcutaneously with 25x10 at week 13 post stem cell transfer⁵Human RL follicular lymphoma cells (ATCC CRL-2261; insensitive to the direct antiproliferative effects of IFN). Mice were treated intraperitoneally with 30 μ g of human Flt3L protein from day 9 to day 22 after tumor inoculation. On day 9 post tumor inoculation, when palpable tumors were visible, i.v. injections of buffer or Fc-AFN (7.5 μ g) construct as described in example 5 were started once a week (n ═ 6 mice/group). Tumor size (caliper measurements), body weight and temperature were assessed daily. The data in figure 9 shows tumor growth up to one week after the third treatment and indicates that both constructs induce strong levels of tumor growth inhibition. The body weight and temperature data did not show any significant difference between buffer treatment and AFN treatment, confirming that all AFN treatments were well tolerated.

Example 7: additional Fc-AFN constructs based on A145G and M148A mutationsThe following additional Fc constructs with attenuated human interferon α 2 were generated:

A.hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-10＊GGS-G-hlFNa2_T106E_M148A

B.hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-10＊GGS-G-hlFNa2_M148A

C.hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-10＊GGS-G-hlFNa2_T106E_A145G

D.hlgG1 Fc_L234A_L235A_K322Q_S354C_T366W-10＊GGS-G-hlFNa2_A145G

E.hlgG1 Fc-L234A-L235A_K322Q_T366Y-10＊GGS-G-hlFNa2_T106E-M148A

F.hlgG1 Fc_L234A_L235A_K322Q_T366Y-10＊GGS-G-hlFNa2_M148A

G.hlgG1 Fc_L234A_L235A_K322Q_T366Y-10＊GGS-G-hlFNa2_T106E_A145G

H，hlgG1 Fc_L234A_L235A_K322Q_T366Y-10＊GGS-G-hlFNa2_A145G

to generate human CLEC 9A-targeted AFNs, any of the above constructs a-D were combined with CLEC9A VHH-Fc fusions of SEQ ID 2 or 4, resulting in 8 novel constructs. Furthermore, combining any of the above constructs E-H with CLEC9A VHH-Fc fusions of SEQ ID 1 or 3, an additional set of 8 novel constructs was generated. The protein was expressed and purified as described in example 5.

Example 8: A145G mutation with or without T106O-glycosylation

In this experiment, Clec 9A-targeted AFN (R1CHCl50-Fc3+ Fc4-IFNa2_ A145G and R1CHCl50-Fc3+ Fc4-IFNa2_ T106E _ A145G) with or without T106O-glycosylation in IFNa2 was compared to non-targeted variants (Fc3+ Fc4-IFNa2_ A145G). The protein was produced as described in example 5 and purified by protein a chromatography followed by size exclusion.

To assess potency, STAT1 phosphorylation of the constructs was tested in primary cDC1(CLEC9A +/CD141+) and non-cDC 1(CLEC9A-/CD141-) populations in human PBMC as described in example 5. Figure 10 shows the specificity of CLEC9A targeting construct with or without T106O-glycosylation, showing that this construct activates IFN signaling more efficiently in cDC1 cells than non-cDC 1 cells and more efficiently on cDC1 cells than cDC1 cells treated with non-targeting variants.

To evaluate the in vivo efficacy of the aforementioned heterodimeric "knob-into-hole" Fc AFN constructs, they were tested in a tumor model in humanized mice. Simply comeIn other words, neonatal NSG mice (1-2 days old) were sub-lethally irradiated with 100cGy and then delivered intrahepatically 1x10⁵Individual CD34+ human stem cells (from HLA-a2 positive cord blood). Mice were inoculated subcutaneously with 25x10 at week 13 post stem cell transfer⁵Human RL follicular lymphoma cells (ATCC CRL-2261; insensitive to the direct antiproliferative effects of IFN). Mice were treated intraperitoneally with 30 μ g of human Flt3L protein from day 7 to day 17 after tumor inoculation. On day 9 post tumor inoculation, when palpable tumors were visible, i.v. injections of buffer or Fc-AFN (2.5 μ g) construct (n ═ 5 mice/group) were started once a week. Tumor size (caliper measurements), body weight and temperature were assessed daily. The data in fig. 11 show tumor growth up to one week after the third treatment and indicate that both targeted AFNs induced strong tumor growth levels, while no significant effect was observed for the untargeted variants. The body weight and temperature data did not show any significant difference between buffer treatment and AFN treatment, confirming that all AFN treatments were well tolerated.

Sequence of

1.P-1479：R1CHCL50-Fc3

2.P-1542：Fc3

3.P-2157：Fc4-IFNa2_

4.P-2158：Fc4-IFNa2_

Example 9: Fc-AFN constructs

Mass spectrometry analysis showed that the C-terminal lysine K residue in the R1CHCl50-Fc3 chain was cleaved off in almost all mature proteins. Thus, a variant in which the lysine residue in both Fc chains was removed was constructed. The resulting protein will be referred to as Fc' protein. As an example, the sequence of a chimeric protein combination of R1CHCL50-Fc3 'with Fc 4' -AFN fusion is shown below, wherein residue a145 in IFNa2b is mutated to G, or wherein residues T106 and a145 in IFNa2a are mutated to E and G, respectively.

The sequence is as follows:

P-2379：Fc4′-IFNa2b-A145G

P-2380：Fc4′-IFNa2a_T106E_A145G

P-1479b：R1CHCL50-Fc3″

sequence listing

<110> Olympus Biosciences Inc (Orionis Biosciences, Inc.)

Olympus bioscience group (Orionis Biosciences BV)

Nigla. Kelei (Kley, Nikolai)

Erick. Depra (Depla, Erik)

Zabeau, Znnart)

Simple Taverail (Tavernier, Jan)

<120> CLEC 9A-based chimeric protein complex

<130> ORN-063PC/114384-5063

<150> US 62/906,442

<151> 2019-09-26

<150> US 62/825,584

<151> 2019-03-28

<160> 43

<170> PatentIn version 3.5

<210> 1

<211> 357

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 1

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys

355

<210> 2

<211> 357

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 2

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys

355

<210> 3

<211> 357

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 3

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Ser Val Asn

20 25 30

Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys

85 90 95

Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys

355

<210> 4

<211> 357

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 4

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Ser Val Asn

20 25 30

Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys

85 90 95

Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys

355

<210> 5

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 5

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 6

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 6

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 7

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 7

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 8

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 8

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 9

<211> 165

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 9

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu Lys Asp

20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln

35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe

50 55 60

Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu

65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu

85 90 95

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys

100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu

115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg

130 135 140

Ala Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser

145 150 155 160

Leu Arg Ser Lys Glu

165

<210> 10

<211> 164

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 10

Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met

1 5 10 15

Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys Asp

20 25 30

Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln

35 40 45

Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe

50 55 60

Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu

65 70 75 80

Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu

85 90 95

Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met Lys

100 105 110

Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu

115 120 125

Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Trp Arg Ala

130 135 140

Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser Leu

145 150 155 160

Arg Ser Lys Glu

<210> 11

<211> 115

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 11

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

<210> 12

<211> 115

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 12

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Ser Val Asn

20 25 30

Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys

85 90 95

Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

<210> 13

<211> 227

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 13

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Thr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 14

<211> 227

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 14

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 15

<211> 227

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 15

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 16

<211> 227

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 16

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 17

<211> 487

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 17

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro

130 135 140

Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser

145 150 155 160

Ile Asn Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu

165 170 175

Leu Val Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser

180 185 190

Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val

195 200 205

Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr

210 215 220

Cys Tyr Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu

225 230 235 240

Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro

260 265 270

Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

275 280 285

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

290 295 300

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp

305 310 315 320

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr

325 330 335

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

340 345 350

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu

355 360 365

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

370 375 380

Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys

385 390 395 400

Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp

405 410 415

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

420 425 430

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser

435 440 445

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser

450 455 460

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

465 470 475 480

Leu Ser Leu Ser Pro Gly Lys

485

<210> 18

<211> 487

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 18

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

355 360 365

Ser Gly Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val

370 375 380

Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe

385 390 395 400

Ser Ser Ile Asn Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu

405 410 415

Arg Glu Leu Val Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala

420 425 430

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn

435 440 445

Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val

450 455 460

Tyr Tyr Cys Tyr Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly

465 470 475 480

Thr Leu Val Thr Val Ser Ser

485

<210> 19

<211> 553

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 19

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

355 360 365

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

370 375 380

Gly Gly Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg

385 390 395 400

Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser

405 410 415

Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly

420 425 430

Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile

435 440 445

Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp

450 455 460

Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu

465 470 475 480

Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr

485 490 495

Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln

500 505 510

Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp

515 520 525

Glu Val Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn

530 535 540

Leu Gln Glu Ser Leu Arg Ser Lys Glu

545 550

<210> 20

<211> 487

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 20

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn

20 25 30

Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu

65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His

85 90 95

Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro

130 135 140

Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser

145 150 155 160

Ile Asn Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu

165 170 175

Leu Val Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser

180 185 190

Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val

195 200 205

Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr

210 215 220

Cys Tyr Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu

225 230 235 240

Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro

260 265 270

Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys

275 280 285

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val

290 295 300

Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp

305 310 315 320

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr

325 330 335

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp

340 345 350

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu

355 360 365

Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg

370 375 380

Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys

385 390 395 400

Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp

405 410 415

Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys

420 425 430

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser

435 440 445

Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser

450 455 460

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser

465 470 475 480

Leu Ser Leu Ser Pro Gly Lys

485

<210> 21

<211> 487

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 21

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

355 360 365

Ser Gly Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val

370 375 380

Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile

385 390 395 400

Phe Ser Ile Asn Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln

405 410 415

Arg Glu Leu Val Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala

420 425 430

Asp Ser Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys

435 440 445

Thr Val Ser Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val

450 455 460

Tyr Tyr Cys His Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly

465 470 475 480

Thr Gln Val Thr Val Ser Ser

485

<210> 22

<211> 553

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 22

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Thr Ile Phe Ser Ile Asn

20 25 30

Arg Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Leu Ile Thr Ser Asp Gly Thr Pro Ala Tyr Ala Asp Ser Ala Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Val Ser Leu

65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His

85 90 95

Val Ser Ser Gly Val Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

355 360 365

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

370 375 380

Gly Gly Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg

385 390 395 400

Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser

405 410 415

Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly

420 425 430

Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile

435 440 445

Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp

450 455 460

Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu

465 470 475 480

Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr

485 490 495

Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln

500 505 510

Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp

515 520 525

Glu Val Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn

530 535 540

Leu Gln Glu Ser Leu Arg Ser Lys Glu

545 550

<210> 23

<211> 647

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 23

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala

1 5 10 15

Ser Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu

20 25 30

Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp

35 40 45

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp

50 55 60

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly

65 70 75 80

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn

85 90 95

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

100 105 110

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly

115 120 125

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu

130 135 140

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn

145 150 155 160

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

165 170 175

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr

180 185 190

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys

195 200 205

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys

210 215 220

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

225 230 235 240

Ser Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

245 250 255

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

260 265 270

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

275 280 285

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

290 295 300

Gly Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro

305 310 315 320

Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Ser

325 330 335

Val Asn Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu

340 345 350

Leu Val Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp Ser

355 360 365

Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Thr Val

370 375 380

Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr

385 390 395 400

Cys Lys Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr Gln

405 410 415

Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

420 425 430

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

435 440 445

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

450 455 460

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

465 470 475 480

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

485 490 495

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

500 505 510

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

515 520 525

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

530 535 540

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

545 550 555 560

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

565 570 575

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

580 585 590

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

595 600 605

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

610 615 620

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

625 630 635 640

Glu Ser Leu Arg Ser Lys Glu

645

<210> 24

<211> 647

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 24

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly

1 5 10 15

Val His Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln

20 25 30

Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe

35 40 45

Ser Val Asn Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg

50 55 60

Glu Leu Val Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp

65 70 75 80

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Thr

85 90 95

Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr

100 105 110

Tyr Cys Lys Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr

115 120 125

Gln Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

130 135 140

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

145 150 155 160

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

165 170 175

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

180 185 190

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

195 200 205

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

210 215 220

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

225 230 235 240

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

245 250 255

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

260 265 270

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

275 280 285

Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala

290 295 300

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

305 310 315 320

Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

325 330 335

Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

340 345 350

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

355 360 365

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu

370 375 380

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

385 390 395 400

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

405 410 415

Leu Ser Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

420 425 430

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

435 440 445

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

450 455 460

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

465 470 475 480

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

485 490 495

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

500 505 510

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

515 520 525

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

530 535 540

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

545 550 555 560

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

565 570 575

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

580 585 590

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

595 600 605

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

610 615 620

Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn Leu Gln

625 630 635 640

Glu Ser Leu Arg Ser Lys Glu

645

<210> 25

<211> 353

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 25

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ile Phe Ser Val Asn

20 25 30

Ala Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

35 40 45

Ala Ala Ile Thr Asn Gln Gly Ala Pro Thr Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Gly Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Lys

85 90 95

Ala Phe Thr Arg Gly Asp Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr

100 105 110

Val Ser Ser Val Asp Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

115 120 125

Ser Gly Gly Ser Gly Gly Ser Arg Ser Gly Gly Ser Gly Gly Ser Gly

130 135 140

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

145 150 155 160

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

165 170 175

Ala Ala Ala Met Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg

180 185 190

Arg Thr Leu Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser

195 200 205

Cys Leu Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly

210 215 220

Asn Gln Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile

225 230 235 240

Gln Gln Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp

245 250 255

Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu

260 265 270

Asn Asp Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr

275 280 285

Pro Leu Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln

290 295 300

Arg Ile Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp

305 310 315 320

Glu Val Val Arg Ala Glu Ile Met Ala Ser Phe Ser Leu Ser Thr Asn

325 330 335

Leu Gln Glu Ser Leu Arg Ser Lys Glu Leu Glu His His His His His

340 345 350

His

<210> 26

<211> 402

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 26

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val His Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Thr

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

130 135 140

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

145 150 155 160

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Asp

165 170 175

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly

180 185 190

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

195 200 205

Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu

210 215 220

Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His

225 230 235 240

Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg

245 250 255

Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys

260 265 270

Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu

275 280 285

Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys

290 295 300

Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu

305 310 315 320

Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp

325 330 335

Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val

340 345 350

Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp

355 360 365

Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His

370 375 380

Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro

385 390 395 400

Gly Lys

<210> 27

<211> 452

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 27

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

260 265 270

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Cys

275 280 285

Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu

290 295 300

Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg

305 310 315 320

His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln Lys

325 330 335

Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn

340 345 350

Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu Leu

355 360 365

Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala

370 375 380

Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu Met Lys Glu

385 390 395 400

Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu Tyr

405 410 415

Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Gly

420 425 430

Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser Leu

435 440 445

Arg Ser Lys Glu

450

<210> 28

<211> 452

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 28

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

260 265 270

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Cys

275 280 285

Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu Met Leu

290 295 300

Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu Lys Asp Arg

305 310 315 320

His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe Gln Lys

325 330 335

Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile Phe Asn

340 345 350

Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr Leu Leu

355 360 365

Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu Glu Ala

370 375 380

Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu Met Lys Glu

385 390 395 400

Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr Leu Tyr

405 410 415

Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val Arg Ala

420 425 430

Glu Ile Ala Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu Ser Leu

435 440 445

Arg Ser Lys Glu

450

<210> 29

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 29

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Ala Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 30

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 30

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Ala Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 31

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 31

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 32

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 32

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 33

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 33

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Ala Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 34

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 34

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Ala Glu Ile Ala Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 35

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 35

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 36

<211> 423

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 36

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Tyr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

225 230 235 240

Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

245 250 255

Ser Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr

260 265 270

Leu Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu

275 280 285

Lys Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln

290 295 300

Phe Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln

305 310 315 320

Ile Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu

325 330 335

Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp

340 345 350

Leu Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu

355 360 365

Met Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile

370 375 380

Thr Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val

385 390 395 400

Val Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln

405 410 415

Glu Ser Leu Arg Ser Lys Glu

420

<210> 37

<400> 37

000

<210> 38

<211> 227

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 38

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Lys

225

<210> 39

<400> 39

000

<210> 40

<400> 40

000

<210> 41

<211> 422

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 41

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

225 230 235 240

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

245 250 255

Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu

260 265 270

Met Leu Leu Ala Gln Met Arg Arg Ile Ser Leu Phe Ser Cys Leu Lys

275 280 285

Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe

290 295 300

Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile

305 310 315 320

Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr

325 330 335

Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu

340 345 350

Glu Ala Cys Val Ile Gln Gly Val Gly Val Thr Glu Thr Pro Leu Met

355 360 365

Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr

370 375 380

Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val

385 390 395 400

Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu

405 410 415

Ser Leu Arg Ser Lys Glu

420

<210> 42

<211> 422

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 42

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly

1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met

20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val

50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr

65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

85 90 95

Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala Pro Ile

100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val

115 120 125

Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

130 135 140

Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu

145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro

165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met

195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser

210 215 220

Pro Gly Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly

225 230 235 240

Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser

245 250 255

Gly Cys Asp Leu Pro Gln Thr His Ser Leu Gly Ser Arg Arg Thr Leu

260 265 270

Met Leu Leu Ala Gln Met Arg Lys Ile Ser Leu Phe Ser Cys Leu Lys

275 280 285

Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Gly Asn Gln Phe

290 295 300

Gln Lys Ala Glu Thr Ile Pro Val Leu His Glu Met Ile Gln Gln Ile

305 310 315 320

Phe Asn Leu Phe Ser Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Thr

325 330 335

Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu

340 345 350

Glu Ala Cys Val Ile Gln Gly Val Gly Val Glu Glu Thr Pro Leu Met

355 360 365

Lys Glu Asp Ser Ile Leu Ala Val Arg Lys Tyr Phe Gln Arg Ile Thr

370 375 380

Leu Tyr Leu Lys Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val

385 390 395 400

Arg Gly Glu Ile Met Arg Ser Phe Ser Leu Ser Thr Asn Leu Gln Glu

405 410 415

Ser Leu Arg Ser Lys Glu

420

<210> 43

<211> 356

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<223> synthetic sequence

<400> 43

Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Phe Ser Ser Ile Asn

20 25 30

Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Glu Leu Val

35 40 45

Ala Arg Ile Thr Asn Leu Gly Leu Pro Asn Tyr Ala Asp Ser Val Lys

50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu

65 70 75 80

Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr

85 90 95

Leu Val Ala Leu Lys Ala Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly

115 120 125

Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala

130 135 140

Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr

145 150 155 160

Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val

165 170 175

Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val

180 185 190

Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser

195 200 205

Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu

210 215 220

Asn Gly Lys Glu Tyr Lys Cys Gln Val Ser Asn Lys Ala Leu Pro Ala

225 230 235 240

Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro

245 250 255

Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln

260 265 270

Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala

275 280 285

Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr

290 295 300

Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu

305 310 315 320

Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser

325 330 335

Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser

340 345 350

Leu Ser Pro Gly

355